SCHEMBL2170303

SCHEMBL2170303

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1S(=O)(=O)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MMP2 P08253 1/20 0.43
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CTSG P08311 1/20 0.37
CMA1 P23946 1/20 0.37
KCNA3 P22001 1/20 0.37
HSD11B1 P28845 2/20 0.35
CHRM1 P11229 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
CHRM4 P08173 1/20 0.35
CYP3A4 P08684 1/20 0.34
HTR6 P50406 1/20 0.34
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169948 0.86 KMT2A (0.44) MEN1KMT2AALDH1A1MMP2POLB
SCHEMBL2170125 0.86 SMN1; SMN2 (0.37) MEN1KMT2AALDH1A1MMP2POLB
SCHEMBL2170001 0.79 FAAH (0.40) KMT2ACTSGCMA1HSD11B1CHRM4
SCHEMBL2170408 0.77 KMT2A (0.42) MEN1KMT2AALDH1A1HSD11B1
SCHEMBL2169997 0.76 CTSG (0.40) ALDH1A1POLBCTSGCMA1HSD11B1
SCHEMBL2168942 0.74 NPSR1 (0.42) MEN1KMT2AALDH1A1L3MBTL1HSD11B1
SCHEMBL2170139 0.74 HSD11B1 (0.40) MEN1KMT2AALDH1A1HSD11B1
SCHEMBL2169563 0.73 P2RX7 (0.40) MEN1KMT2AALDH1A1KCNA3HSD11B1
SCHEMBL2169487 0.69 PDCD1 (0.40) MEN1KMT2AALDH1A1
SCHEMBL2168859 0.69 NR1H4 (0.39) MEN1KMT2AALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
WO-2010050191-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME 興和株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 MEN1 490/4885KMT2A 3619/4885ALDH1A1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.